Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,140 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Flu Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults

NCT01250795
View directory record Official record
Conditions
Healthy
Interventions
HAI-05 Influenza Vaccine, Saline
Biological · Other
Lead sponsor
Fraunhofer, Center for Molecular Biotechnology
Industry
Eligibility
18 Years to 49 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Wichita, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 21, 2026, 5:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03 or MF59

NCT06560151
View directory record Official record
Conditions
Influenza
Interventions
3.75 µg H5N8 antigen plus full dose AS03A, 7.5 µg H5N8 antigen plus full dose AS03A, 15 µg H5N8 antigen plus full dose AS03A, 3.75 µg H5N8 antigen plus half dose AS03A, 7.5 µg H5N8 antigen plus half dose AS03A, 15 µg H5N8 antigen plus half dose AS03A, 3.75 µg H5N8 antigen plus MF59, 7.5 µg H5N8 antigen plus MF59, 15 µg H5N8 antigen plus MF59, 3.75 µg H5N1 antigen plus full dose AS03A, 7.5 µg H5N1 antigen plus full dose AS03A, 15 µg H5N1 antigen plus full dose AS03A, 3.75 µg H5N1 antigen plus MF59, 7.5 µg H5N1 antigen plus MF59, 15 µg H5N1 antigen plus MF59
Biological
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years and older
Enrollment
1,380 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
20
States / cities
Atlanta, Georgia • Savannah, Georgia • Oak Lawn, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 21, 2026, 5:55 AM EDT
Not listed Not applicable Interventional

Immunogenicity of Influenza Vaccine in Long Term Care

NCT02933723
View directory record Official record
Conditions
Influenza
Interventions
Blood Draw
Procedure
Lead sponsor
Insight Therapeutics, LLC
Other
Eligibility
65 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 21, 2026, 5:55 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection

NCT06999603
View directory record Official record
Conditions
Viral Pneumonia
Interventions
SNG001, Placebo
Drug
Lead sponsor
Synairgen Research Ltd.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 21, 2026, 5:55 AM EDT
Completed Not applicable Interventional Results available

Patient Portal Flu Vaccine Reminders (5)

NCT05525494
View directory record Official record
Conditions
Influenza, Respiratory Tract Infections
Interventions
Text Fixed R/R Messages with Direct Appointment Schedule Link, Text Pre-Appointment Reminder, Portal Pre-Commitment Prompt with Tailored R/R Messages with Direct Appointment Schedule Link, Portal Fixed R/R Messages with Direct Appointment Schedule Link, Portal Pre-Appointment Reminder
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
6 Months and older
Enrollment
262,085 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 21, 2026, 5:55 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Reverse Genetic H9N2 Influenza Vaccine Study in Adults

NCT01320696
View directory record Official record
Conditions
Influenza
Interventions
Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine
Biological
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
5
States / cities
Huntsville, Alabama • Melbourne, Florida • Peoria, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 21, 2026, 5:55 AM EDT
Completed Not applicable Interventional

Assessing Fever Rates in Children Ages 24 to 59 Months After Live Attenuated Influenza Vaccine (LAIV) or Inactivated Influenza Vaccines (IIV) Using Text Messaging for U.S. Influenza Vaccines in 2012-2013 & 2013-2014

NCT01764269
View directory record Official record
Conditions
Fever
Interventions
text message surveillance for fever
Other
Lead sponsor
Columbia University
Other
Eligibility
24 Months to 59 Months
Enrollment
656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Oct 21, 2026, 5:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Post-Partum Immunization With Live Attenuated Influenza Vaccine (LAIV) or Trivalent Influenza Vaccine (TIV) in Post-Partum Breast Feeding Women

NCT01181323
View directory record Official record
Conditions
Influenza
Interventions
Placebo, Cold-adapted live attenuated influenza virus vaccine, trivalent, Trivalent inactivated influenza vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years · Female only
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2015 · Synced Oct 21, 2026, 5:55 AM EDT
Completed Not applicable Interventional

Adult Influenza Vaccination Text Message Reminders With Electronic Health Record Alerts

NCT02284594
View directory record Official record
Conditions
Influenza
Interventions
text message
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
4,026 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Oct 21, 2026, 5:55 AM EDT
Terminated No phase listed Observational Results available

Clinical Validation of the Point-of-Care MSD Influenza Test

NCT00863343
View directory record Official record
Conditions
Influenza Human
Interventions
Public Health Notification
Biological
Lead sponsor
Meso Scale Diagnostics, LLC.
Industry
Eligibility
Not listed
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
San Diego, California • Lebanon, New Hampshire • Port Jefferson, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2012 · Synced Oct 21, 2026, 5:55 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older

NCT00765076
View directory record Official record
Conditions
Influenza
Interventions
GSK Biologicals' influenza vaccine GSK2186877A, GSK Biologicals' Fluarix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 21, 2026, 5:55 AM EDT
Completed No phase listed Observational

"Quidel Reader Influenza A + B Test 510(k) and CLIA Waiver Field Study"

NCT01309568
View directory record Official record
Conditions
Influenza
Interventions
Not listed
Lead sponsor
Quidel Corporation
Industry
Eligibility
Not listed
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
16
States / cities
Carlsbad, California • Panorama City, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 12, 2011 · Synced Oct 21, 2026, 5:55 AM EDT
Completed Phase 1 Interventional

HIV Vaccine Designed for HIV Infected Adults Taking Anti-HIV Drugs

NCT00056758
View directory record Official record
Conditions
HIV Infections
Interventions
Autologous Dendritic Cell HIV Vaccination
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 27, 2007 · Synced Oct 21, 2026, 5:55 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Impact of Metabolic Syndrome on Flu Vaccine Efficacy

NCT02653495
View directory record Official record
Conditions
Immune Deficiency, Metabolic Syndrome
Interventions
Influenza vaccine
Biological
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Oct 21, 2026, 5:55 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Immunologic Response to Influenza Vaccination in Children and Adolescents

NCT03614975
View directory record Official record
Conditions
Influenza, Human, Immune Response
Interventions
Flucelvax inactivated influenza vaccine, Fluzone inactivated influenza vaccine
Biological
Lead sponsor
Richard Zimmerman MD
Other
Eligibility
4 Years to 20 Years
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 21, 2026, 5:55 AM EDT
Terminated Phase 1 Interventional

Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)

NCT03396575
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma (DIPG), Brain Stem Glioma
Interventions
TTRNA-DC vaccines with GM-CSF, TTRNA-xALT, Cyclophosphamide + Fludarabine Lymphodepletive Conditioning, Dose-Intensified TMZ, Td vaccine, Autologous Hematopoietic Stem Cells (HSC)
Biological · Drug
Lead sponsor
University of Florida
Other
Eligibility
3 Years to 30 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 21, 2026, 5:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Comparison of Full-dose Flu Vaccine to Half-dose Flu Vaccine

NCT00283283
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® (Aventis Pasteur inactivated influenza vaccine)
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 64 Years
Enrollment
1,316 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 12, 2021 · Synced Oct 21, 2026, 5:55 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy Adults Compared With Placebo

NCT06435936
View directory record Official record
Conditions
PHA1A
Interventions
Single Ascending Dose of SAB-176, Single Ascending Dose of Placebo
Drug
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 21, 2026, 5:55 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination

NCT02485639
View directory record Official record
Conditions
Influenza, Influenza Immunisation
Interventions
Influenza Virus Vaccine Inactivated
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 21, 2026, 5:55 AM EDT
Completed No phase listed Observational

BD Veritor™ At-Home and BD Veritor™ Professional

NCT05352581
View directory record Official record
Conditions
Upper Respiratory Infection
Interventions
BD Veritor At-Home, BD Veritor Professional
Diagnostic Test
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
2 Years and older
Enrollment
1,146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
9
States / cities
Coconut Creek, Florida • Palm Springs, Florida • Pembroke Pines, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 21, 2026, 5:55 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About mRNA Vaccines Against Influenza in Adults

NCT07431853
View directory record Official record
Conditions
Healthy Adults
Interventions
Vaccine Candidate #1, Vaccine Candidate #2, Vaccine Candidate #3, Vaccine Candidate #4, Vaccine Candidate #5, Vaccine Candidate #6, TIV1 or TIV2
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
770 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
15
States / cities
Mobile, Alabama • Walnut Creek, California • Milford, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 21, 2026, 5:55 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)

NCT01773928
View directory record Official record
Conditions
Influenza
Interventions
Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified), VCIV manufactured with the current manufacturing process (VCIV current), Fluzone®, licensed trivalent influenza vaccine (TIV)
Biological
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,928 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
20
States / cities
Chandler, Arizona • Anaheim, California • Paramount, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 21, 2026, 5:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)

NCT00783926
View directory record Official record
Conditions
Influenza, Pandemic Influenza
Interventions
H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen)
Biological
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
422 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
6
States / cities
Wichita, Kansas • Lexington, Kentucky • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 21, 2026, 5:55 AM EDT
Completed Not applicable Interventional Results available

Nudging Flu Vaccination by Making it Easy for Patients to Schedule a Flu Shot

NCT05493787
View directory record Official record
Conditions
Influenza
Interventions
Reminder
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
139,503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Oct 21, 2026, 5:55 AM EDT